Denmark's Genmab to acquire ProfoundBio for $1.8 billion

-0.51%

-3.07%

-1.07%

-1.69%

Dow Jones Industrial Average DJI	48458.05	-0.51%
Genmab A/S GMAB	31.31	-3.07%
S&P 500 index SPX	6827.41	-1.07%
NASDAQ IXIC	23195.17	-1.69%

April 3 (Reuters) - Danish biotech Genmab GMAB.CO has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.

The acquisition will give Genmab worldwide rights to three candidates in clinical development, they added.

The all-cash transaction is subject to adjustment for ProfoundBio's closing net debt and transaction expenses.

(Reporting by Elviira Luoma, editing by Terje Solsvik)

((Elviira.luoma@thomsonreuters.com))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.